title: Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
abstract: This pooled analysis of six prospective, multicentre trials aimed to determine the efficacy of moxifloxacin in community-acquired pneumonia (CAP) due to penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae (MDRSP). At a central laboratory, isolates were identified and antimicrobial susceptibility determined (microbroth dilution). MDRSP was defined as resistance > or =3 drug classes. Patients received oral or sequential intravenous/oral 400 mg moxifloxacin once daily for 7-14 days. The primary endpoint was clinical success at test-of-cure for efficacy-valid patients with proven pretherapy S. pneumoniae infection. Of 140 S. pneumoniae isolated (112 respiratory, 28 blood), 23 (16.4%) were penicillin resistant, 26 (18.6%) macrolide resistant and 31 (22.1%) MDRSP. The moxifloxacin MIC90 was 0.25 microg/ml. Clinical cure with moxifloxacin was 95.4% (125/131) overall, and 100% (21/21) for penicillin-, 95.7% (22/23) for macrolide- and 96.4% (27/28) for multidrug-resistant strains. Moxifloxacin provided excellent clinical and bacteriological cure rates in CAP due to drug-resistant pneumococci.
authors.affiliation: Lung and Chest Medical Associates, Spartanburg, SC 29303, USA.
authors.forename: C
authors.initials: C
authors.lastname: Fogarty
authors.forename: A
authors.initials: A
authors.lastname: Torres
authors.forename: S
authors.initials: S
authors.lastname: Choudhri
authors.forename: D
authors.initials: D
authors.lastname: Haverstock
authors.forename: J
authors.initials: J
authors.lastname: Herrington
authors.forename: J
authors.initials: J
authors.lastname: Ambler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D018942:Macrolides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D010403:Penicillin Resistance; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D013296:Streptococcus pneumoniae / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D018942:Macrolides; D011804:Quinolines; D000077266:Moxifloxacin